By Harshit
WASHINGTON, MARCH 15, 2026 — Every prescription drug on the shelves of every American pharmacy went through one of the most rigorous review processes in the world before it got there. Most Americans have no idea how that process actually works — or that the FDA just made its biggest change to drug approvals in more than 60 years. Here is everything you need to know.
Why the FDA Exists
The U.S. Food and Drug Administration’s entire purpose in the drug approval space comes down to one question: do this drug’s benefits outweigh its risks? Every review, every clinical trial, every data submission, and every inspector visit to a manufacturing facility is designed to answer that question with the highest possible certainty before a drug reaches a single patient.
The FDA doesn’t test drugs itself. Pharmaceutical companies do — and they fund the entire research and development process. The FDA’s job is to independently review the evidence those companies generate and decide, based on that evidence alone, whether the drug is safe and effective enough to sell in the United States.
The Five Stages Every Drug Must Pass
Getting a drug approved takes between 12 and 15 years from initial concept to pharmacy shelf. The process is divided into five distinct stages, each designed to answer a progressively more complex set of questions about the drug’s behavior in the human body.
The first stage is discovery and preclinical research. Scientists identify a compound that appears to have a useful biological effect, synthesize it in a laboratory, and test it extensively in animal models to screen for basic toxicity. Of every 5,000 compounds that enter preclinical testing, roughly five make it to human trials.
The second stage is clinical research — the heart of the entire process. Clinical trials are divided into three phases. Phase 1 trials, typically involving 20 to 100 healthy volunteers, test the drug’s safety and determine how the body processes it. Phase 2 trials expand to several hundred patients with the target condition and begin evaluating whether the drug actually works. Phase 3 trials are the most demanding — typically involving thousands of patients across multiple sites, randomized and controlled, designed to confirm efficacy and detect rarer side effects that smaller trials might have missed. Only about 25% of drugs that enter Phase 1 trials survive all three phases.
The third stage is FDA review. Once clinical trials are complete, the drug company submits a New Drug Application containing every study, every data point, and every proposed label it has generated. An independent team of FDA physicians and scientists — separate from the company’s own researchers — reviews the entire submission. Standard review takes 10 months. Priority Review, granted to drugs that address unmet medical needs, runs six months.
The fourth stage is FDA approval — the formal determination that the drug’s benefits outweigh its known risks and that it can be manufactured consistently and safely at commercial scale. The fifth stage, often overlooked, is post-market safety monitoring. Approval is not the end of FDA scrutiny. The agency continues tracking real-world safety data indefinitely after a drug reaches market, and has the authority to require label changes, impose new restrictions, or withdraw approval entirely if new safety signals emerge.
The Special Designations That Speed Things Up
For drugs targeting serious or life-threatening conditions, the FDA has developed four pathways that can dramatically compress the standard timeline.
Fast Track designation is granted to drugs that treat serious conditions and fill an unmet medical need. It allows the drug company to submit completed sections of its application on a rolling basis rather than waiting until everything is finished — shaving months off the review timeline.
Breakthrough Therapy designation goes further, reserved for drugs with preliminary clinical evidence showing substantial improvement over existing treatments. It triggers intensive FDA guidance throughout the development process to help the company design the most efficient trials possible.
Accelerated Approval allows drugs for serious conditions to reach patients based on a surrogate endpoint — a measurable indicator, like tumor shrinkage, that is reasonably likely to predict the actual clinical benefit, like survival. Post-approval trials must still confirm the real-world benefit, and the FDA can revoke accelerated approval if those confirmatory studies fall short.
Priority Review simply shortens the FDA’s review clock from 10 months to six — granted when the drug offers a significant improvement in safety or effectiveness over available treatments.
The Biggest Change in 60 Years — What Just Happened in 2026
In February 2026, FDA Commissioner Dr. Martin Makary and his deputy Dr. Vinay Prasad announced the most significant overhaul of the drug approval standard since the early 1960s. In a commentary published in the New England Journal of Medicine, they declared that the FDA’s longstanding default requirement of two separate clinical trials to prove a drug’s effectiveness was officially ending.
Going forward, the FDA’s default position is that a single well-controlled study, combined with confirmatory evidence, is sufficient for marketing authorization of novel drugs. The change affects primarily medications for common diseases — cancer and rare disease treatments had already been routinely approved on single trials for years. Approximately 60% of new drugs approved over the past five years had already cleared on one study, meaning the formal rule was already out of step with standard practice.
Supporters argue the change will accelerate access to life-saving treatments and reduce costs for drug developers. Critics worry it weakens the evidentiary standard that has protected American patients from ineffective or unsafe drugs for decades. The FDA maintains that advances in scientific understanding and data analysis make a second confirmatory trial unnecessary in most cases — and that requiring one adds years to approval timelines without meaningfully improving safety outcomes.
Whatever the debate, the change is now policy. The FDA that approves drugs in 2026 operates by different rules than the one that approved them in 2025 — and every American who takes a prescription drug has a stake in understanding what that means.
